SCHEMBL10348175

SCHEMBL10348175

NNc1nccc(-c2ccccc2)c1Cl

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LRRK2 Q5S007 2/20 0.41
MAP4K4 O95819 2/20 0.41
PRKACA P17612 2/20 0.41
IKBKB O14920 1/20 0.41
CHUK O15111 1/20 0.41
DAPK3 O43293 1/20 0.41
JAK2 O60674 1/20 0.41
PRKD3 O94806 1/20 0.41
PAK4 O96013 1/20 0.41
CSF1R P07333 1/20 0.41
RET P07949 1/20 0.41
IGF1R P08069 1/20 0.41
FGFR1 P11362 1/20 0.41
FLT1 P17948 1/20 0.41
LTK P29376 1/20 0.41
GRK5 P34947 1/20 0.41
KDR P35968 1/20 0.41
MAP2K2 P36507 1/20 0.41
MAPK8 P45983 1/20 0.41
CSNK1A1 P48729 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL740063 0.86 LTA4H (0.43) IKBKBKDRALKALDH1A1MAPT
SCHEMBL4491842 0.83 KDM4E (0.41) LRRK2KDRCDK5GSK3BALDH1A1
SCHEMBL9838637 0.80 LRRK2 (0.42) LRRK2MAP4K4PRKACAIKBKBCHUK
SCHEMBL30582967 0.80 LRRK2 (0.42) LRRK2MAP4K4PRKACAIKBKBCHUK
SCHEMBL3301267 0.76 BACE1 (0.41) LRRK2MAP4K4PRKACAIKBKBCHUK
SCHEMBL7861011 0.75 LRRK2 (0.43) LRRK2MAP4K4PRKACAIKBKBCHUK
SCHEMBL28083706 0.73 CCNA2 (0.44) LRRK2MAP4K4PRKACAIKBKBCHUK
SCHEMBL30147779 0.72 AXL (0.36) LRRK2CDK9CDK5AURKBGOT1
SCHEMBL18940676 0.72 AXL (0.36) LRRK2CDK9CDK5AURKBGOT1
SCHEMBL11620059 0.70 ALDH1A1 (0.42) LRRK2MAP4K4PRKACAIKBKBCHUK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9085577-B2 7-aryl-1,2,4-triazolo[4,3-A]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors Janssen Pharmaceuticals, Inc. (US) 2015-07-21 US disclosed
US-20140200208-A1 7-ARYL-1,2,4-TRIAZOLO[4,3-A]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS ADDEX PHARMA, S.A. (CH) 2014-07-17 US disclosed
US-8716480-B2 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors Janssen Pharmaceuticals, Inc. (US) 2014-05-06 US disclosed
EP-2430021-B1 7-ARYL-1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF mGluR2 RECEPTORS JANSSEN PHARMACEUTICALS INC (US) 2013-08-28 EP disclosed
US-20120184528-A1 7-ARYL-1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS ADDEX PHARMA S.A. (CH) 2012-07-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140200208-A1 7-ARYL-1,2,4-TRIAZOLO[4,3-A]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS GRM2, GRM1, GRIA2 LRRK2 676/4885MAP4K4 1370/4885PRKACA 3647/4885
US-20120184528-A1 7-ARYL-1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS GRM2, GRM1, GRIA2 LRRK2 676/4885MAP4K4 1370/4885PRKACA 3647/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.